https://www.selleckchem.com/products/mycro-3.html
S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development. CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigato
Like
Comment
Share
